[1\]Kohno Y,Takeuchi SPharmacological profiles and clinical effects of antiparkinsonian agent,pramipexole\[J\]Nippon Yakurigaku Zasshi,2004,123:439\|440.
\[2\]Izumi Y,Sawada H,Yamamoto N,et alNovel neuroprotective mechanisms of pramipexole,an anti\|Parkinson drug,against endogenous dopamine\|mediated excitotoxicity\[J\]Eur J Pharmacol,2007,557:132\|140
\[3\]Joyce JN,Woolsey C,Ryoo H.Low dose pramipexole is neuroprotective in the MPTP mouse of Parkinsons disease,and downregulates the dopamine transporter via the D3 receptor\[J\]BMC Biol,2004,2:22
\[4\]Shannon KM,Bennett JP Jr,Friedman JHEfficacy oj pramipexole,a novel dopamine agonist,as monotherapy in mild to moderate Parkinsons diseaseThe Pramipexole Study Group\[J\]Neurology,1997,49:724\|728
\[5\]Nirenberg MJ,Water CCompulsive eating and weight gain related o dopamine agonist use\[J\]Mov Disord,2006,21:524\|529
|